Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Prostatic Diseases 1Genital Neoplasms, Male 1Genital Diseases, Male 1

Interventions

padeliporfin 5darolutamide 3Pluvicto 3gallium 68 PSMA-11 2enzalutamide 2apalutamide 2Radiotherapy 2Nivolumab 2Androgen Antagonists 2Abiraterone Acetate 2talazoparib 1sipuleucel-T 1palladium-bacteriopheophorbide 1onapristone 1olaparib 1niraparib 1luprolide acetate gel depot 1ixabepilone 1gedatolisib 1abiraterone 1Therapeutics 1Tamsulosin 1Surveys and Questionnaires 1Standard of Care 1Robotic Surgical Procedures 1Prostate-Specific Antigen 1Prednisone 1Paclitaxel 1Oxygen 1Nitrous Oxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Diseases × EPI-506 × Genitourinary × Clear all
NCT02606123 2018-03-01

Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer

ESSA Pharmaceuticals

Phase 1/2 Terminated
28 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Prostatic Diseases, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡